PROVIDE-HF- Patient Reported Outcomes investigation following Initiation of Drug therapy with Entresto (Sacubitril/Valsartan) in Heart Failure
Purpose: To look at the change in patient-reported HF symptoms via the KCCQ following the initiation of sacubitril/valsartan (continuous measure) through 12-weeks.
Study Design: Prospective Study.
• PCORnet Partners:
PaTH Partners: Geisinger Health System, Johns Hopkins University, University of Pittsburgh, University of Utah
How to participate: Contact Kristin Shoemaker, RN, BSN, CCRC at 412-682-2769